JP2017533200A - ナルゲニシン化合物及び抗菌剤としてのそれの使用 - Google Patents

ナルゲニシン化合物及び抗菌剤としてのそれの使用 Download PDF

Info

Publication number
JP2017533200A
JP2017533200A JP2017521550A JP2017521550A JP2017533200A JP 2017533200 A JP2017533200 A JP 2017533200A JP 2017521550 A JP2017521550 A JP 2017521550A JP 2017521550 A JP2017521550 A JP 2017521550A JP 2017533200 A JP2017533200 A JP 2017533200A
Authority
JP
Japan
Prior art keywords
alkyl
arya
ring
heta
nhc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017521550A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017533200A5 (https=
Inventor
ヤング,キャサリン
オルセン,デイヴィッド・ビー
シング,シェオ・ビー
スー,ジン
ヴィルクナン,ロバート・アール
アプガー,ジェームズ・エム
メン,ドンファン
パーカー,ダン
マンダール,ミハイル
ヤン,リフュ
ペインター,ロナルド・イー
ダン,クン
鈴木 隆雄
隆雄 鈴木
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of JP2017533200A publication Critical patent/JP2017533200A/ja
Publication of JP2017533200A5 publication Critical patent/JP2017533200A5/ja
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08Bridged systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01Sulfonic acids
    • C07C309/02Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/06Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing halogen atoms, or nitro or nitroso groups bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16Halogenated acetic acids
    • C07C53/18Halogenated acetic acids containing fluorine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/12Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains three hetero rings
    • C07D493/18Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP2017521550A 2014-10-22 2015-10-21 ナルゲニシン化合物及び抗菌剤としてのそれの使用 Pending JP2017533200A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2014/089204 2014-10-22
PCT/CN2014/089204 WO2016061772A1 (en) 2014-10-22 2014-10-22 Nargenicin compounds and uses thereof as antibacterial agents
PCT/US2015/056627 WO2016064982A1 (en) 2014-10-22 2015-10-21 Nargenicin compounds and uses thereof as antibacterial agents

Publications (2)

Publication Number Publication Date
JP2017533200A true JP2017533200A (ja) 2017-11-09
JP2017533200A5 JP2017533200A5 (https=) 2019-10-17

Family

ID=55760063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017521550A Pending JP2017533200A (ja) 2014-10-22 2015-10-21 ナルゲニシン化合物及び抗菌剤としてのそれの使用

Country Status (11)

Country Link
US (2) US9944654B2 (https=)
EP (1) EP3209667B1 (https=)
JP (1) JP2017533200A (https=)
KR (1) KR20170070197A (https=)
CN (1) CN107108646A (https=)
AU (1) AU2015335992A1 (https=)
BR (1) BR112017008101A2 (https=)
CA (1) CA2964377A1 (https=)
MX (1) MX2017005271A (https=)
RU (1) RU2017117253A (https=)
WO (2) WO2016061772A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016061772A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents
KR102440647B1 (ko) 2020-07-28 2022-09-06 선문대학교 산학협력단 나르제니신 a1 유도체를 포함하는 항혈관신생용 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351769A (en) * 1980-08-25 1982-09-28 The Upjohn Company Antibiotic composition of matter
US4360683A (en) * 1980-08-06 1982-11-23 The Upjohn Company Antibiotic nodusmicin derivatives
US4448970A (en) * 1981-02-19 1984-05-15 The Upjohn Company Nargenicin derivatives
JPS5998087A (ja) * 1982-10-21 1984-06-06 フアイザ−・インコ−ポレ−テツド ナルゲニシンc↓1

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4148883A (en) 1977-08-18 1979-04-10 Pfizer Inc. Antibiotics produced by new species of nocardia
US4605624A (en) * 1982-10-21 1986-08-12 Pfizer Inc. Nocardia species capable of producing nargenicin C1
ES2258234T3 (es) 2002-08-12 2006-08-16 PHARMACIA & UPJOHN COMPANY LLC N-aril-2-oxazolidinonas y sus derivados.
GB0227701D0 (en) 2002-11-28 2003-01-08 Astrazeneca Ab Chemical compounds
MXPA05005522A (es) 2002-11-28 2005-07-25 Astrazeneca Ab Oxazolidinonas como agentes antibacterianos.
WO2005012270A2 (en) 2003-07-29 2005-02-10 Rib-X Pharmaceuticals, Inc. Biaryl heterocyclic amines, amides, and sulfur-containing compounds and methods of making and using the same
KR100854211B1 (ko) 2003-12-18 2008-08-26 동아제약주식회사 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물
JP2008500318A (ja) 2004-05-25 2008-01-10 アストラゼネカ アクチボラグ 抗菌剤としての3−{4−(ピリジン−3−イル)フェニル}−5−(1h−1,2,3−トリアゾール−1−イルメチル)−1,3−オキサゾリジン−2−オン
WO2007133803A2 (en) 2006-05-15 2007-11-22 Rib-X Pharmaceuticals, Inc. Treatment of mycobacterial infections
WO2008069619A1 (en) 2006-12-08 2008-06-12 Legochem Bioscience Ltd. Novel oxazolidinone derivatives, process for preparing thereof and pharmaceutical composition containing the same
KR101040468B1 (ko) 2008-02-29 2011-06-09 조선대학교산학협력단 새로운 노카르디아 속 균주 및 그의 발효 배양물의 용도
KR101022564B1 (ko) 2008-12-19 2011-03-16 조선대학교산학협력단 나르제니신을 포함하는 염증성 신경퇴행성 질환의 치료용 제약 조성물
WO2011139832A2 (en) 2010-04-28 2011-11-10 Rib-X Pharmaceuticals, Inc. Method for treating mycobacterial infections
KR101561964B1 (ko) 2013-11-15 2015-10-20 한국과학기술연구원 옥사졸리디논 화합물 및 이를 포함하는 c형 간염 예방 또는 치료용 약학 조성물
WO2016061772A1 (en) 2014-10-22 2016-04-28 Merck Sharp & Dohme Corp. Nargenicin compounds and uses thereof as antibacterial agents

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4360683A (en) * 1980-08-06 1982-11-23 The Upjohn Company Antibiotic nodusmicin derivatives
US4351769A (en) * 1980-08-25 1982-09-28 The Upjohn Company Antibiotic composition of matter
US4448970A (en) * 1981-02-19 1984-05-15 The Upjohn Company Nargenicin derivatives
JPS5998087A (ja) * 1982-10-21 1984-06-06 フアイザ−・インコ−ポレ−テツド ナルゲニシンc↓1

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"「結核医療の基準」の見直し—2014年", 結核, vol. 89(7), JPN7019001745, 2014, pages 683 - 690, ISSN: 0004217480 *
BOSHOFF, H. I.M. ET AL.: "DnaE2 Polymerase Contributes to In Vivo Survival and the Emergence of Drug Resistance in Mycobacteri", CELL, vol. 113(2), JPN6019020042, 2003, pages 183 - 193, ISSN: 0004045671 *
CELMER, W. D. ET AL.: "Structure of Natural Antibiotic CP-47,444", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 102(12), JPN6019020035, 1980, pages 4203 - 4309, ISSN: 0004217476 *
MAGERLEIN, BARNEY J. ET AL.: "9-O-Esters of nodusmicin", JOURNAL OF ANTIBIOTICS, vol. 35(1), JPN6019020032, 1982, pages 111 - 112, ISSN: 0004217474 *
PLATA, DANIEL J. ET AL.: "Total Synthesis of (+)-18-Deoxynargenicin A1", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 110(12), JPN6019020036, 1988, pages 4041 - 4042, ISSN: 0004217477 *
SNYDER, WILLIAM C. ET AL.: "Biosynthesis of Nargenicin and Nodusmicin", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 106(3), JPN6019020033, 1984, pages 787 - 789, ISSN: 0004217475 *
WHALEY, H. A. ET AL.: "Nodusmicin: the structure of a new antibiotic", TETRAHEDRON LETTERS, vol. 21(38), JPN6019020038, 1980, pages 3659 - 3662, ISSN: 0004217478 *
朝野和典: "7. MRSA感染 診断と治療の最新の知見", 日本内科学会雑誌, vol. 99(9), JPN6019020039, 2010, pages 246 - 251, ISSN: 0004217479 *

Also Published As

Publication number Publication date
CN107108646A (zh) 2017-08-29
KR20170070197A (ko) 2017-06-21
EP3209667A1 (en) 2017-08-30
CA2964377A1 (en) 2016-04-28
RU2017117253A (ru) 2018-11-23
EP3209667A4 (en) 2018-06-06
RU2017117253A3 (https=) 2019-04-16
AU2015335992A1 (en) 2017-04-20
US10144741B2 (en) 2018-12-04
WO2016064982A1 (en) 2016-04-28
EP3209667B1 (en) 2025-03-19
US9944654B2 (en) 2018-04-17
WO2016061772A1 (en) 2016-04-28
MX2017005271A (es) 2017-08-15
US20180186808A1 (en) 2018-07-05
BR112017008101A2 (pt) 2018-02-20
US20170305924A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
CN108135887B (zh) 噁唑烷酮化合物及其作为抗菌剂的使用方法
RU2733402C2 (ru) Бициклические арильные монобактамовые соединения и способы их применения для лечения бактериальных инфекций
JP2020536082A (ja) 細菌感染症を治療するためのクロマンモノバクタム化合物
US10144741B2 (en) Nargenicin compounds and uses thereof as antibacterial agents
JP2008532938A (ja) 抗感染薬としての新規なイソチアゾロキノロンおよび関連化合物
WO2020147504A1 (en) Oxazolidinone compounds and methods of use thereof as antibacterial agents
US10752621B2 (en) Oxazolidinone compounds and methods of use thereof as antibacterial agents
CA3145555C (en) Compounds and methods of use thereof as antibacterial agents
TW201429972A (zh) 抗菌噁唑酮衍生物
TWI917443B (zh) 作為抗菌劑之化合物及其使用方法
JP2021504489A (ja) 抗菌複素環式化合物及びそれらの合成
RU2794494C2 (ru) Оксазолидиноновые соединения и способы их применения в качестве противобактериальных средств
EA046711B1 (ru) Соединения и способы их применения в качестве антибактериальных агентов

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180919

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180919

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190530

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190604

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20190904

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20200225